XNASAMLX
Market cap265mUSD
Dec 27, Last price
3.87USD
1D
-4.91%
1Q
25.65%
IPO
-76.85%
Name
Amylyx Pharmaceuticals Inc
Chart & Performance
P/E
5.38
P/S
0.70
EPS
0.72
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
381m
+1,612.94%
Net income
49m
P
CFO
12m
P
Dividend
Mar 28, 20180.42 USD/sh
Earnings
Jun 06, 2025
Profile
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 380,786 1,612.94% | 22,230 7,700.00% | 285 -56.15% | ||
Cost of revenue | 341,984 | 227,971 | 83,025 | ||
Unusual Expense (Income) | |||||
NOPBT | 38,802 | (205,741) | (82,740) | ||
NOPBT Margin | 10.19% | ||||
Operating Taxes | 5,026 | 774 | (52) | ||
Tax Rate | 12.95% | ||||
NOPAT | 33,776 | (206,515) | (82,688) | ||
Net income | 49,271 -124.84% | (198,375) 125.74% | (87,879) 96.00% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 3,543 | 431,789 | 135,000 | ||
BB yield | -0.34% | -17.57% | |||
| Debt | |||||
Debt current | 4,514 | 2,040 | |||
Long-term debt | 6,217 | 10,514 | |||
Deferred revenue | 35 | ||||
Other long-term liabilities | 239,351 | ||||
Net debt | (360,631) | (335,110) | (96,307) | ||
| Cash flow | |||||
Cash from operating activities | 11,919 | (179,871) | (74,799) | ||
CAPEX | (1,241) | (2,526) | (353) | ||
Cash from investing activities | 92,053 | (238,988) | (46,406) | ||
Cash from financing activities | 3,543 | 431,789 | 158,506 | ||
FCF | 19,724 | (214,176) | (83,011) | ||
| Balance | |||||
Cash | 371,362 | 346,945 | 96,118 | ||
Long term investments | 719 | 189 | |||
Excess cash | 352,323 | 346,552 | 96,293 | ||
Stockholders' equity | (304,745) | 37,154 | (148,160) | ||
Invested Capital | 744,671 | 309,730 | 236,378 | ||
ROIC | 6.41% | ||||
ROCE | 8.82% | ||||
| EV | |||||
Common stock shares outstanding | 69,991 | 66,512 | 57,864 | ||
Price | 14.72 -60.16% | 36.95 | |||
Market cap | 1,030,273 -58.08% | 2,457,619 | |||
EV | 669,642 | 2,513,962 | |||
EBITDA | 39,890 | (205,254) | (82,688) | ||
EV/EBITDA | 16.79 | ||||
Interest | 4,291 | ||||
Interest/NOPBT | |||||